Description of the sample from the gout clinic at Hospital de Cruces
| Variable | N | Value |
| Sex (male), n (%) | 1192 | 1095 (91.9) |
| Age (years), m±SD | 1192 | 60.8±13.6 |
| Diagnosis, n (%) | 1192 | |
| Clinical | 178 (14.9) | |
| Microscopy | 942 (79.0) | |
| Ultrasound | 72 (6.0) | |
| Disease duration (years), median (P25–P75) | 1187 | 4 (2–10) |
| Clinical evolution, n (%) | 1184 | |
| Tophi without arthritis | 3 (0.2) | |
| Monoarticular | 176 (14.9) | |
| Oligoarticular | 573 (48.4) | |
| Polyarticular | 432 (36.5) | |
| Number of flares in the previous year, median (P25–P75) | 1179 | 2 (2–4) |
| Tophi, n (%) | 1191 | 398 (33.4) |
| sUA (baseline) (mg/dL), m±SD | 1181 | 9.1±1.5 |
| sUA levels during follow-up after optimisation, n (%) | 1095 | |
| <0.36 mmol/L | 916 (83.6) | |
| ≥0.36 mmol/L | 179 (16.3) | |
| Comorbidity and risk factors | ||
| BMI (kg/m2), m±SD | 1173 | 28.1±4.0 |
| Creatinine (baseline) (mg/dL), m±SD | 1176 | 1.27±0.89 |
| Creatinine clearance (mL/min), m±SD | 1044 | 73.3±33.0 |
| Ethanol consumption >20 g/day, n (%) | 1171 | 378 (32.3) |
| Arterial hypertension, n (%) | 1172 | 606 (51.7) |
| Diabetes, n (%) | 1171 | 235 (20.1) |
| Hyperlipidaemia, n (%) | 1170 | 565 (48.3) |
| Previous CV event, n (%) | 1171 | 363 (31.0) |
| Urate lithiasis, n (%) | 1170 | 97 (8.3) |
| Treatment | 1192 | |
| Urate-lowering drugs, n (%) | 1190 | 483 (40.5) |
| First-line treatment, n (%) | ||
| Without treatment | 133 (11.2) | |
| Allopurinol | 740 (62.2) | |
| Benzbromarone | 213 (17.9) | |
| Febuxostat | 104 (8.7) |
BMI, body mass index; CV, cardiovascular; m, mean; sUA, serum uric acid.